Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Isentress (Raltegravir, MK-0518)

The Basics | Research

Show Archived (Historical) Articles

Brand Name:	Isentress
Generic Name:	Raltegravir, MK-0518
Adult Single Dose:	One 400-mg tablet twice daily
Food & Liquid Restrictions:	None
Drug Class:	Integrase Inhibitor

From The Body's "Ask the Experts" Forums

» More questions

The Basics

An Overview of Isentress (Raltegravir, MK-0518) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Isentress (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
HIV/AIDS Update: Traditional Approval of Isentress (raltegravir) (February 5, 2009)
From U.S. Food and Drug Administration
Isentress (Raltegravir, MK-0518) Patient Product Information (PDF) (January 2009)
From Merck & Co., Inc.
Patient Information About Isentress (Raltegravir, MK-0518) (PDF) (January 2009)
From Merck & Co., Inc.
Raltegravir (Isentress) (December 13, 2008)
To read PDF, click here
From AIDS InfoNet
Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (November 3, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
Comparing Two Integrase Inhibitors (September/October 2008)
The first head-to-head study comparing raltegravir and elvitegravir.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Letter Sent by Merck to the Fair Pricing Coalition Announcing ADAP Price Freeze of Isentress (PDF) (August 1, 2008)
From Merck & Co., Inc.
Isentress (Raltegravir) (January 8, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Mr. Sharp Goes to Washington (November/December 2007)
Advocating for a new drug before the FDA.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
How Isentress Works: An Interview With David Wohl, M.D. (Part II) (October 23, 2007)
A detailed look at how Isentress works.
From The Body
The Bottom Line on Isentress: An Interview With David Wohl, M.D. (Part I) (October 23, 2007)
An overview of Isentress.
From The Body
Project Inform Reacts to Approval, Pricing of Isentress (October 15, 2007)
From Project Inform
FDA Approval of Isentress (Raltegravir) (October 12, 2007)
From U.S. Food and Drug Administration
Isentress (Raltegravir) Pricing: Community Sign-On Letter (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News

Research

Could Isentress Be Used as an HIV Prevention Drug? (April 28, 2009)
From aidsmap.com
Raltegravir as First-Line Therapy (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Study Explains Why Isentress Works Well and Resists Resistance (October 26, 2008)
From Project Inform
Raltegravir May Cause Temporary Worsening of Pre-Existing Depression (September 2, 2008)
From aidsmap.com
HIV-1 Integrase Inhibitors (June 23, 2008)
An overview on a new HIV medication class.
In The PRN Notebook
ICAAC 2007 Study Summaries: An Interview With Joseph Eron, M.D. (September 20, 2007)
Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced HIVers.
From The Body PRO
Briefing Document (Background Package): Raltegravir (PDF) (September 5, 2007)
FDA Antiviral Drugs Advisory Committee Meeting.
From U.S. Food and Drug Administration
Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
FDA Grants Speedy Review for First HIV Integrase Inhibitor (June 29, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
77% of Treatment-Experienced Patients on MK-0518 (raltegravir) Plus OBT Achieve Viral Load of Less Than 400 Copies: A Study Summary From David Cooper, M.D., and Roy Steigbigel, Ph.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
New Experimental Drug Integrase Inhibitor (MK-0518) (October/November 2006)
In Survival News, from AIDS Survival Project
MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
EARMRK: Expanded Access Research Program for MK-0518 (PDF) (August 17, 2006)
From Merck & Co., Inc.
Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options (August 17, 2006)
Worldwide access program will be conducted along with phase III studies.
To read PDF, click here
From Merck & Co., Inc.
Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients (August 17, 2006)
In XVI International AIDS Conference
Integrase Inhibitors: The Next Wave? (Spring 2006)
A quick look at MK-518 and GS-9137.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.